2020
Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma
Berger Y, Schuitevoerder D, Vining C, Alpert L, Fenton E, Hindi E, Liao C, Shergill A, Catenacci D, Polite B, Eng O, Turaga K. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Annals Of Surgical Oncology 2020, 28: 1777-1785. PMID: 32892267, DOI: 10.1245/s10434-020-09064-7.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyCytoreductive surgerySystemic chemotherapyIntraperitoneal chemotherapySurvival outcomesMedian overall survivalUnresectable peritoneal metastasesMatched group of patientsExtensive bowel involvementGroup of patientsComplete cytoreductionAppendiceal tumorsPeritoneal metastasisTumor burdenBackgroundPeritoneal metastasisOverall survivalBowel obstructionBowel involvementPoor prognosisMedian lengthHigh-gradeChemotherapyMitomycin CPatientsMatched group
2015
Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multi‐institutional analysis
Tabrizian P, Jayakrishnan T, Zacharias A, Aycart S, Johnston F, Sarpel U, Labow D, Turaga K. Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multi‐institutional analysis. Journal Of Surgical Oncology 2015, 111: 1035-1040. PMID: 26040443, DOI: 10.1002/jso.23924.Peer-Reviewed Original ResearchConceptsDiagnostic laparoscopyPeritoneal metastasisPort site recurrenceManagement of patientsComplete cytoreductionSite recurrenceCases of port site recurrenceMulti-institutional analysisHigh-volume institutionsRisk of port site recurrenceColorectal primaryIncomplete cytoreductionSystemic chemotherapyPredominant histologyOverall survivalOptical trocarHostile abdomenRetrospective reviewLaparoscopyVeress needleCytoreductionSerosal injuryPatientsMetastasisHIPEC
2014
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
Helm J, Miura J, Glenn J, Marcus R, Larrieux G, Jayakrishnan T, Donahue A, Gamblin T, Turaga K, Johnston F. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Annals Of Surgical Oncology 2014, 22: 1686-1693. PMID: 25124472, DOI: 10.1245/s10434-014-3978-x.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansHyperthermia, InducedLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantNeoplasm StagingPeritoneal NeoplasmsPrognosisConceptsEarly postoperative intraperitoneal chemotherapyHyperthermic intraperitoneal chemotherapyMalignant peritoneal mesotheliomaCytoreductive surgeryIntraperitoneal chemotherapyMeta-analysis of observational studiesPeritoneal mesotheliomaMeta-analysisPeritoneal carcinomatosis index scoreImproved 5-year survivalHeterogeneity of studiesPostoperative intraperitoneal chemotherapyMeta-regression techniquesMethodsThe reviewFunnel plotComplete cytoreductionPublication biasSystematic reviewPooled estimatesSurvival benefitMedian ageCalculate standard errorsImproved survivalChemotherapyObservational studyThe American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery
Prada‐Villaverde A, Esquivel J, Lowy A, Markman M, Chua T, Pelz J, Baratti D, Baumgartner J, Berri R, Bretcha‐Boix P, Deraco M, Flores‐Ayala G, Glehen O, Gomez‐Portilla A, González‐Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres‐Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Journal Of Surgical Oncology 2014, 110: 779-785. PMID: 25088304, DOI: 10.1002/jso.23728.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic AgentsChemotherapy, Cancer, Regional PerfusionColorectal NeoplasmsCombined Modality TherapyDigestive System Surgical ProceduresFemaleFollow-Up StudiesHumansHyperthermia, InducedInjections, IntraperitonealMaleMiddle AgedMitomycinNeoplasm StagingOrganoplatinum CompoundsOxaliplatinPeritoneal NeoplasmsPrognosisRetrospective StudiesSurvival RateConceptsPeritoneal Surface Disease Severity ScoreHyperthermic intraperitoneal chemotherapyAmerican Society of Peritoneal Surface MalignanciesOverall survivalMitomycin CCytoreductive surgeryOS ratesMedian overall survivalPeritoneal surface malignanciesMitomycin C groupDisease severity scoresAmerican SocietyComplete cytoreductionPeritoneal carcinomatosisIntraperitoneal chemotherapySurface malignanciesOxaliplatin groupIII/IV patientsProspective studyOxaliplatinColon cancerColorectal cancerCytoreductionSeverity scorePatients
2005
Long-term Survival Following Treatment of Pseudomyxoma Peritonei
Miner T, Shia J, Jaques D, Klimstra D, Brennan M, Coit D. Long-term Survival Following Treatment of Pseudomyxoma Peritonei. Annals Of Surgery 2005, 241: 300-308. PMID: 15650641, PMCID: PMC1356916, DOI: 10.1097/01.sla.0000152015.76731.1f.Peer-Reviewed Original ResearchConceptsPseudomyxoma peritoneiComplete cytoreductionTumor biologyRecurrence of pseudomyxoma peritoneiTreatment of pseudomyxoma peritoneiMemorial Sloan-Kettering Cancer CenterPathological featuresLow-grade pathologyMedian overall survivalAssociated with tumor biologyContribution of tumor biologyDisease-free intervalDiagnosis of pseudomyxoma peritoneiTen-year survivalCompleteness of follow-upLong-term survivalOverall survivalImproved survivalPatient selectionCytoreductionPathological subtypesFollow-upPatient characteristicsControl symptomsCancer Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply